CN3 PHARMACOECONOMIC (PE) ANALYSIS OF THE TREATMENT OF NON-SMALL CELL LUNG CANCER (NSCLC) IN THE NETHERLANDS DEMONSTRATES THAT ERLOTINIB DOMINATES DOCETAXEL AND IS COST-EFFECTIVE OVER BEST SUPPORTIVE CARE (BSC) WITHOUT NEED FOR PATIENT STRATIFICATION
| Verfasser: | |
|---|---|
| Dokumenttyp: | Artikel |
| Erscheinungsdatum: | 2006 |
| Reihe/Periodikum: | Value in Health ; volume 9, issue 6, page A203 ; ISSN 1098-3015 |
| Verlag/Hrsg.: |
Elsevier BV
|
| Sprache: | Englisch |
| Permalink: | https://search.fid-benelux.de/Record/base-28763562 |
| Datenquelle: | BASE; Originalkatalog |
| Powered By: | BASE |
| Link(s) : | http://dx.doi.org/10.1016/s1098-3015(10)63205-6 |
